– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 10 February 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or the “Company”), a biotechnology company dedicated to developing disease ...
Tag: 2025
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 3 February 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it raised capital in the U.S. to accelerate clinical development and business development activities for the Company’s lead asset, ATH434. Based ...
– Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied – – Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale – – Key MRI Biomarker Shows Iron Stabilization in MSA Affected Brain Regions – – ATH434 Demonstrated a Favorable Safety Profile – – Webcast Today at 11:00 a.m. ...
Alterity Therapeutics released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 December 2024 (Q2 FY25).
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 17 January 2025: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, has released a Shareholder Newsletter. You can access the full newsletter in this link: https://mailchi.mp/we-worldwide/alterity-therapeutics-shareholder-newsletter-january-2025 Below is an excerpt of the newsletter, a ...